Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)

Trial Profile

Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Olaparib (Primary) ; Cabazitaxel; Carboplatin; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 Planned primary completion date changed from 27 Mar 2020 to 27 Oct 2020.
    • 03 Oct 2017 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.
    • 03 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top